Advertisement

Cardiovascular Disease in Large Vessel Vasculitis

Risks, Controversies, and Management Strategies

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Egebjerg K.
        • Baslund B.
        • Obel N.
        • et al.
        Mortality and cardiovascular morbidity among patients diagnosed with Takayasu’s arteritis: a Danish nationwide cohort study.
        Clin Exp Rheumatol. 2020; 38 Suppl 124: 91-94
        • Lee Y.H.
        • Song G.G.
        Overall and cause-specific mortality in giant cell arteritis : a meta-analysis.
        Z Rheumatol. 2018; 77: 946-951
        • Uddhammar A.
        • Eriksson A.-L.
        • Nyström L.
        • et al.
        Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden.
        J Rheumatol. 2002; 29: 737-742
        • Watanabe R.
        • Berry G.J.
        • Liang D.H.
        • et al.
        Pathogenesis of giant cell arteritis and takayasu arteritis-similarities and differences.
        Curr Rheumatol Rep. 2020; 22: 68
        • Onen F.
        • Akkoc N.
        Epidemiology of Takayasu arteritis.
        Presse Médicale. 2017; 46: e197-e203
        • Weyand C.M.
        • Goronzy J.J.
        Medium- and large-vessel vasculitis.
        N Engl J Med. 2003; 349: 160-169
        • Kerr G.S.
        • Hallahan C.W.
        • Giordano J.
        • et al.
        Takayasu arteritis.
        Ann Intern Med. 1994; 120: 919-929
        • Saadoun D.
        • Vautier M.
        • Cacoub P.
        Medium- and large-vessel vasculitis.
        Circulation. 2021; 143: 267-282
        • Mirouse A.
        • Biard L.
        • Comarmond C.
        • et al.
        Overall survival and mortality risk factors in Takayasu’s arteritis: a multicenter study of 318 patients.
        J Autoimmun. 2019; 96: 35-39
        • Lupi-Herrera E.
        • Sánchez-Torres G.
        • Marcushamer J.
        • et al.
        Takayasu’s arteritis. Clinical study of 107 cases.
        Am Heart J. 1977; 93: 94-103
        • Ishikawa K.
        • Maetani S.
        Long-term outcome for 120 Japanese patients with Takayasu’s disease. Clinical and statistical analyses of related prognostic factors.
        Circulation. 1994; 90: 1855-1860
        • Kim H.
        • Barra L.
        Ischemic complications in Takayasu’s arteritis: a meta-analysis.
        Semin Arthritis Rheum. 2018; 47: 900-906
        • Alibaz-Oner F.
        • Koster M.J.
        • Unal A.U.
        • et al.
        Assessment of the frequency of cardiovascular risk factors in patients with Takayasu’s arteritis.
        Rheumatol Oxf Engl. 2017; 56: 1939-1944
        • Liu Q.
        • Dang A.
        • Lv N.
        • et al.
        Anaemia and low body mass index are associated with increased cardiovascular disease in patients with Takayasu arteritis.
        Clin Exp Rheumatol. 2016; 34: S16-S20
        • Kwon O.C.
        • Park J.H.
        • Park Y.-B.
        • et al.
        Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis.
        Arthritis Res Ther. 2020; 22: 180
        • Rav-Acha M.
        • Plot L.
        • Peled N.
        • et al.
        Coronary involvement in Takayasu’s arteritis.
        Autoimmun Rev. 2007; 6: 566-571
        • Endo M.
        • Tomizawa Y.
        • Nishida H.
        • et al.
        Angiographic findings and surgical treatments of coronary artery involvement in Takayasu arteritis.
        J Thorac Cardiovasc Surg. 2003; 125: 570-577
        • Wang H.
        • Liu Z.
        • Shen Z.
        • et al.
        Impact of coronary involvement on long-term outcomes in patients with Takayasu’s arteritis.
        Clin Exp Rheumatol. 2020; 38: 1118-1126
        • Lei C.
        • Huang Y.
        • Yuan S.
        • et al.
        Takayasu arteritis with coronary artery involvement: differences between pediatric and adult patients.
        Can J Cardiol. 2020; 36: 535-542
        • Fan L.
        • Zhang H.
        • Cai J.
        • et al.
        Clinical course and prognostic factors of childhood Takayasu’s arteritis: over 15-year comprehensive analysis of 101 patients.
        Arthritis Res Ther. 2019; 21: 31
        • Hotchi M.
        Pathological studies on Takayasu arteritis.
        Heart Vessels Suppl. 1992; 7: 11-17
        • Matsubara O.
        • Kuwata T.
        • Nemoto T.
        • et al.
        Coronary artery lesions in Takayasu arteritis: pathological considerations.
        Heart Vessels Suppl. 1992; 7: 26-31
        • Filer A.
        • Nicholls D.
        • Corston R.
        • et al.
        Takayasu arteritis and atherosclerosis: illustrating the consequences of endothelial damage.
        J Rheumatol. 2001; 28: 2752-2753
        • Tomasson G.
        • Peloquin C.
        • Mohammad A.
        • et al.
        Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study.
        Ann Intern Med. 2014; 160: 73-80
        • Amiri N.
        • De Vera M.
        • Choi H.K.
        • et al.
        Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study.
        Rheumatol Oxf Engl. 2016; 55: 33-40
        • Ungprasert P.
        • Koster M.J.
        • Warrington K.J.
        Coronary artery disease in giant cell arteritis: a systematic review and meta-analysis.
        Semin Arthritis Rheum. 2015; 44: 586-591
        • Li L.
        • Neogi T.
        • Jick S.
        Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink.
        Rheumatol Oxf Engl. 2017; 56: 753-762
        • Lie J.T.
        Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation.
        Semin Arthritis Rheum. 1995; 24: 422-431
        • Wilkinson I.M.
        • Russell R.W.
        Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement.
        Arch Neurol. 1972; 27: 378-391
        • Morris C.R.
        • Scheib J.S.
        Fatal myocardial infarction resulting from coronary arteritis in a patient with polymyalgia rheumatica and biopsy-proved temporal arteritis. A case report and review of the literature.
        Arch Intern Med. 1994; 154: 1158-1160
        • Shan K.S.
        • Zhang Q.
        • Bisaria S.
        • et al.
        A rare case of coronary artery thrombosis in a patient with recently diagnosed giant cell arteritis: is anticardiolipin antibody involved?.
        Cureus. 2020; 12: e8077
        • Banerjee S.
        • Bagheri M.
        • Sandfort V.
        • et al.
        Vascular calcification in patients with large-vessel vasculitis compared to patients with hyperlipidemia.
        Semin Arthritis Rheum. 2019; 48: 1068-1073
        • de Souza A.W.S.
        • Machado N.P.
        • Pereira V.M.
        • et al.
        Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis.
        Circ J Off J Jpn Circ Soc. 2010; 74: 1236-1241
        • Lee G.Y.
        • Jang S.Y.
        • Ko S.M.
        • et al.
        Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center.
        Int J Cardiol. 2012; 159: 14-20
        • Ungprasert P.
        • Wijarnpreecha K.
        • Cheungpasitporn W.
        • et al.
        Inpatient prevalence, burden and comorbidity of Takayasu’s arteritis: Nationwide inpatient sample 2013-2014.
        Semin Arthritis Rheum. 2019; 49: 136-139
        • Duarte M.M.
        • Geraldes R.
        • Sousa R.
        • et al.
        Stroke and transient ischemic attack in takayasu’s arteritis: a systematic review and meta-analysis.
        J Stroke Cerebrovasc Dis. 2016; 25: 781-791
        • Ringleb P.A.
        • Strittmatter E.I.
        • Loewer M.
        • et al.
        Cerebrovascular manifestations of Takayasu arteritis in Europe.
        Rheumatol Oxf Engl. 2005; 44: 1012-1015
        • Bond K.M.
        • Nasr D.
        • Lehman V.
        • et al.
        Intracranial and extracranial neurovascular manifestations of takayasu arteritis.
        AJNR Am J Neuroradiol. 2017; 38: 766-772
        • Seyahi E.
        • Ugurlu S.
        • Cumali R.
        • et al.
        Atherosclerosis in takayasu arteritis.
        Ann Rheum Dis. 2006; 65: 1202-1207
        • Hatri A.
        • Guermaz R.
        • Laroche J.-P.
        • et al.
        [Takayasu’s arteritis and atherosclerosis].
        J Med Vasc. 2019; 44: 311-317
        • Ungprasert P.
        • Wijarnpreecha K.
        • Koster M.J.
        • et al.
        Cerebrovascular accident in patients with giant cell arteritis: A systematic review and meta-analysis of cohort studies.
        Semin Arthritis Rheum. 2016; 46: 361-366
        • Pariente A.
        • Guédon A.
        • Alamowitch S.
        • et al.
        Ischemic stroke in giant-cell arteritis: French retrospective study.
        J Autoimmun. 2019; 99: 48-51
        • Siemonsen S.
        • Brekenfeld C.
        • Holst B.
        • et al.
        3T MRI reveals extra- and intracranial involvement in giant cell arteritis.
        AJNR Am J Neuroradiol. 2015; 36: 91-97
        • Laura D.
        • Keean N.
        • Rebello R.
        • et al.
        Involvement of the intracranial circulation in giant cell arteritis.
        Can J Ophthalmol J Can Ophtalmol. 2020; 55https://doi.org/10.1016/j.jcjo.2020.04.002
        • Samson M.
        • Jacquin A.
        • Audia S.
        • et al.
        Stroke associated with giant cell arteritis: a population-based study.
        J Neurol Neurosurg Psychiatr. 2015; 86: 216-221
        • Gonzalez-Gay M.A.
        • Vazquez-Rodriguez T.R.
        • Gomez-Acebo I.
        • et al.
        Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis.
        Medicine (Baltimore). 2009; 88: 227-235
        • de Boysson H.
        • Liozon E.
        • Larivière D.
        • et al.
        Giant cell arteritis-related stroke: a retrospective multicenter case-control study.
        J Rheumatol. 2017; 44: 297-303
        • Gonzalez-Juanatey C.
        • Lopez-Diaz M.J.
        • Martin J.
        • et al.
        Atherosclerosis in patients with biopsy-proven giant cell arteritis.
        Arthritis Rheum. 2007; 57: 1481-1486
        • Nuenninghoff D.M.
        • Hunder G.G.
        • Christianson T.J.H.
        • et al.
        Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.
        Arthritis Rheum. 2003; 48: 3522-3531
        • Nuenninghoff D.M.
        • Hunder G.G.
        • Christianson T.J.H.
        • et al.
        Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.
        Arthritis Rheum. 2003; 48: 3532-3537
        • García-Martínez A.
        • Arguis P.
        • Prieto-González S.
        • et al.
        Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation).
        Ann Rheum Dis. 2014; 73: 1826-1832
        • Gonzalez-Gay M.A.
        • Garcia-Porrua C.
        • Piñeiro A.
        • et al.
        Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study.
        Medicine (Baltimore). 2004; 83: 335-341
        • Blockmans D.
        • de Ceuninck L.
        • Vanderschueren S.
        • et al.
        Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.
        Arthritis Rheum. 2006; 55: 131-137
        • Prieto-González S.
        • Arguis P.
        • García-Martínez A.
        • et al.
        Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography.
        Ann Rheum Dis. 2012; 71: 1170-1176
        • Koster M.J.
        • Crowson C.S.
        • Labarca C.
        • et al.
        Incidence and predictors of thoracic aortic damage in biopsy-proven giant cell arteritis.
        Scand J Rheumatol. 2021; 50: 239-242
        • Robson J.C.
        • Kiran A.
        • Maskell J.
        • et al.
        The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.
        Ann Rheum Dis. 2015; 74: 129-135
        • Muratore F.
        • Crescentini F.
        • Spaggiari L.
        • et al.
        Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT.
        Semin Arthritis Rheum. 2019; 48: 1074-1082
        • Schmidt W.A.
        • Blockmans D.
        Investigations in systemic vasculitis - The role of imaging.
        Best Pract Res Clin Rheumatol. 2018; 32: 63-82
        • Blockmans D.
        • Coudyzer W.
        • Vanderschueren S.
        • et al.
        Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis.
        Rheumatol Oxf Engl. 2008; 47: 1179-1184
        • Aviña-Zubieta J.A.
        • Bhole V.M.
        • Amiri N.
        • et al.
        The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study.
        Ann Rheum Dis. 2016; 75: 148-154
        • Unizony S.
        • Lu N.
        • Tomasson G.
        • et al.
        Temporal trends of venous thromboembolism risk before and after diagnosis of giant cell arteritis.
        Arthritis Rheumatol Hoboken NJ. 2017; 69: 176-184
        • Numano F.
        • Isohisa I.
        • Kishi U.
        • et al.
        Takayasu’s disease in twin sisters. Possible genetic factors.
        Circulation. 1978; 58: 173-177
        • Numano F.
        • Ohta N.
        • Sasazuki T.
        HLA and clinical manifestations in Takayasu disease.
        Jpn Circ J. 1982; 46: 184-189
        • Kasuya K.
        • Hashimoto Y.
        • Numano F.
        Left ventricular dysfunction and HLA Bw52 antigen in Takayasu arteritis.
        Heart Vessels Suppl. 1992; 7: 116-119
        • Terao C.
        • Yoshifuji H.
        • Kimura A.
        • et al.
        Two susceptibility loci to takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a japanese population.
        Am J Hum Genet. 2013; 93: 289-297
        • Carmona F.D.
        • Mackie S.L.
        • Martín J.-E.
        • et al.
        A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.
        Am J Hum Genet. 2015; 96: 565-580
        • Carmona F.D.
        • Vaglio A.
        • Mackie S.L.
        • et al.
        A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
        Am J Hum Genet. 2017; 100: 64-74
        • Schaefer A.S.
        • Bochenek G.
        • Jochens A.
        • et al.
        Genetic evidence for PLASMINOGEN as a shared genetic risk factor of coronary artery disease and periodontitis.
        Circ Cardiovasc Genet. 2015; 8: 159-167
        • Robson J.C.
        • Kiran A.
        • Maskell J.
        • et al.
        Which patients with giant cell arteritis will develop cardiovascular or cerebrovascular disease? A clinical practice research datalink study.
        J Rheumatol. 2016; 43: 1085-1092
        • Comarmond C.
        • Cluzel P.
        • Toledano D.
        • et al.
        Findings of cardiac magnetic resonance imaging in asymptomatic myocardial ischemic disease in Takayasu arteritis.
        Am J Cardiol. 2014; 113: 881-887
        • da Silva T.F.
        • Levy-Neto M.
        • Bonfá E.
        • et al.
        High prevalence of metabolic syndrome in Takayasu arteritis: increased cardiovascular risk and lower adiponectin serum levels.
        J Rheumatol. 2013; 40: 1897-1904
        • Tomasson G.
        • Bjornsson J.
        • Zhang Y.
        • et al.
        Cardiovascular risk factors and incident giant cell arteritis: a population-based cohort study.
        Scand J Rheumatol. 2019; 48: 213-217
        • Udayakumar P.D.
        • Chandran A.K.
        • Crowson C.S.
        • et al.
        Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study.
        Arthritis Care Res. 2015; 67: 396-402
        • Monti S.
        • Robson J.
        • Klersy C.
        • et al.
        Early development of new cardiovascular risk factors in the systemic vasculitides.
        Clin Exp Rheumatol. 2020; 38 Suppl 124: 126-134
        • de Mornac D.
        • Agard C.
        • Hardouin J.-B.
        • et al.
        Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis.
        Ther Adv Musculoskelet Dis. 2021; 13 (1759720X211006967)
        • Li T.
        • Du J.
        • Gao N.
        • et al.
        Numano type V Takayasu arteritis patients are more prone to have coronary artery involvement.
        Clin Rheumatol. 2020; 39: 3439-3447
        • Wang Z.
        • Dang A.
        • Lv N.
        Brachial-ankle pulse wave velocity is increased and associated with disease activity in patients with takayasu arteritis.
        J Atheroscler Thromb. 2020; 27: 172-182
        • Gonzalez-Juanatey C.
        • Llorca J.
        • Garcia-Porrua C.
        • et al.
        Steroid therapy improves endothelial function in patients with biopsy-proven giant cell arteritis.
        J Rheumatol. 2006; 33: 74-78
        • Laurent C.
        • Prieto-González S.
        • Belnou P.
        • et al.
        Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis.
        Sci Rep. 2021; 11: 14404
        • Reiss A.B.
        • Carsons S.E.
        • Anwar K.
        • et al.
        Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages.
        Arthritis Rheum. 2008; 58: 3675-3683
        • Zimmerman M.C.
        • Clemens D.L.
        • Duryee M.J.
        • et al.
        Direct antioxidant properties of methotrexate: Inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging.
        Redox Biol. 2017; 13: 588-593
        • Shuai Z.-Q.
        • Zhang C.-X.
        • Shuai Z.-W.
        • et al.
        Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis.
        Eur Rev Med Pharmacol Sci. 2021; 25: 250-262
        • Nakaoka Y.
        • Isobe M.
        • Tanaka Y.
        • et al.
        Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
        Rheumatol Oxf Engl. 2020; 59: 2427-2434
        • Yokokawa T.
        • Kunii H.
        • Kaneshiro T.
        • et al.
        Regressed coronary ostial stenosis in a young female with Takayasu arteritis: a case report.
        BMC Cardiovasc Disord. 2019; 19: 79
        • Pan L.
        • Du J.
        • Liu J.
        • et al.
        Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis.
        Clin Rheumatol. 2020; 39: 2369-2378
        • Chung E.S.
        • Packer M.
        • Lo K.H.
        • et al.
        Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.
        Circulation. 2003; 107: 3133-3140
        • Mazlumzadeh M.
        • Hunder G.G.
        • Easley K.A.
        • et al.
        Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
        Arthritis Rheum. 2006; 54: 3310-3318
        • Broder M.S.
        • Sarsour K.
        • Chang E.
        • et al.
        Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis.
        Semin Arthritis Rheum. 2016; 46: 246-252
        • Gale S.
        • Wilson J.C.
        • Chia J.
        • et al.
        Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK.
        Rheumatol Ther. 2018; 5: 327-340
        • Stone J.H.
        • Tuckwell K.
        • Dimonaco S.
        • et al.
        Trial of tocilizumab in giant-cell arteritis.
        N Engl J Med. 2017; 377: 317-328
        • Unizony S.
        • McCulley T.J.
        • Spiera R.
        • et al.
        Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
        Arthritis Res Ther. 2021; 23: 8
        • Gale S.
        • Trinh H.
        • Tuckwell K.
        • et al.
        Adverse events in giant cell arteritis and rheumatoid arthritis patient populations: analyses of tocilizumab clinical trials and claims data.
        Rheumatol Ther. 2019; 6: 77-88
        • Nesher G.
        • Berkun Y.
        • Mates M.
        • et al.
        Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.
        Arthritis Rheum. 2004; 50: 1332-1337
        • Lee M.S.
        • Smith S.D.
        • Galor A.
        • et al.
        Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
        Arthritis Rheum. 2006; 54: 3306-3309
        • Narváez J.
        • Bernad B.
        • Gómez-Vaquero C.
        • et al.
        Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis.
        Clin Exp Rheumatol. 2008; 26: S57-S62
        • Martínez-Taboada V.M.
        • López-Hoyos M.
        • Narvaez J.
        • et al.
        Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis.
        Autoimmun Rev. 2014; 13: 788-794
        • Bienvenu B.
        • Ly K.H.
        • Lambert M.
        • et al.
        Management of giant cell arteritis: recommendations of the french study group for large vessel vasculitis (GEFA).
        Rev Med Interne. 2016; 37: 154-165
        • Mackie S.L.
        • Dejaco C.
        • Appenzeller S.
        • et al.
        British society for rheumatology guideline on diagnosis and treatment of giant cell arteritis.
        Rheumatol Oxf Engl. 2020; 59: e1-e23
        • Hellmich B.
        • Agueda A.
        • Monti S.
        • et al.
        2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
        Ann Rheum Dis. 2020; 79: 19-30
        • Ridker P.M.
        • Rifai N.
        • Pfeffer M.A.
        • et al.
        Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.
        Circulation. 1999; 100: 230-235
        • Kent S.M.
        • Flaherty P.J.
        • Coyle L.C.
        • et al.
        Effect of atorvastatin and pravastatin on serum C-reactive protein.
        Am Heart J. 2003; 145: e8
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.H.
        • et al.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Devaraj S.
        • Siegel D.
        • Jialal I.
        Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?.
        Curr Atheroscler Rep. 2011; 13: 31-42
        • Mora S.
        • Ridker P.M.
        Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?.
        Am J Cardiol. 2006; 97: 33A-41A
        • Pugnet G.
        • Sailler L.
        • Bourrel R.
        • et al.
        Is statin exposure associated with occurrence or better outcome in giant cell arteritis? Results from a French population-based study.
        J Rheumatol. 2015; 42: 316-322
        • de Jong H.J.I.
        • Meyboom R.H.B.
        • Helle M.J.
        • et al.
        Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: a case report.
        Ann Intern Med. 2014; 161: 614-615
        • Pugnet G.
        • Sailler L.
        • Fournier J.-P.
        • et al.
        Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study.
        J Rheumatol. 2016; 43: 2162-2170
        • Narváez J.
        • Bernad B.
        • Nolla J.M.
        • et al.
        Statin therapy does not seem to benefit giant cell arteritis.
        Semin Arthritis Rheum. 2007; 36: 322-327
        • Pearson G.J.
        • Thanassoulis G.
        • Anderson T.J.
        • et al.
        2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
        Can J Cardiol. 2021; (S0828-282X(21)00165-3)https://doi.org/10.1016/j.cjca.2021.03.016